AIxCrypto Holdings (AIXC) Stock Overview
A clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AIXC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AIxCrypto Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.54 |
| 52 Week High | US$8.81 |
| 52 Week Low | US$1.61 |
| Beta | 0.28 |
| 1 Month Change | -28.05% |
| 3 Month Change | 36.56% |
| 1 Year Change | -47.42% |
| 3 Year Change | -97.25% |
| 5 Year Change | -99.86% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M
Aug 16Qualigen Therapeutics files mixed shelf offering of up to $150M
Jul 29Qualigen partners Hande Sciences to support its application enabling studies for QN-302
Jul 06Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?
Mar 08
We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate
Nov 23Shareholder Returns
| AIXC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.0% | 1.6% | -2.1% |
| 1Y | -47.4% | 16.2% | 9.4% |
Return vs Industry: AIXC underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: AIXC underperformed the US Market which returned 9.4% over the past year.
Price Volatility
| AIXC volatility | |
|---|---|
| AIXC Average Weekly Movement | 32.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AIXC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AIXC's weekly volatility has increased from 19% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 4 | Kevin Richardson | qlgntx.com |
AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.
AIxCrypto Holdings, Inc. Fundamentals Summary
| AIXC fundamental statistics | |
|---|---|
| Market cap | US$4.31m |
| Earnings (TTM) | -US$8.09m |
| Revenue (TTM) | n/a |
Is AIXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIXC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$24.68k |
| Gross Profit | -US$24.68k |
| Other Expenses | US$8.07m |
| Earnings | -US$8.09m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 8.4% |
How did AIXC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/22 11:53 |
| End of Day Share Price | 2025/11/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AIxCrypto Holdings, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Bautz | Zacks Small-Cap Research |